- Home
- RAPT vs BIOA Comparison
RAPT vs BIOA Comparison
Compare RAPT & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- BIOA
- Stock Information
- Founded
- RAPT 2015
- BIOA 2015
- Country
- RAPT United States
- BIOA United States
- Employees
- RAPT N/A
- BIOA N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- RAPT Health Care
- BIOA Health Care
- Exchange
- RAPT Nasdaq
- BIOA Nasdaq
- Market Cap
- RAPT 117.5M
- BIOA 139.1M
- IPO Year
- RAPT 2019
- BIOA 2024
- Fundamental
- Price
- RAPT $0.79
- BIOA $3.87
- Analyst Decision
- RAPT Hold
- BIOA Hold
- Analyst Count
- RAPT 7
- BIOA 4
- Target Price
- RAPT $5.00
- BIOA $5.67
- AVG Volume (30 Days)
- RAPT 1.1M
- BIOA 365.5K
- Earning Date
- RAPT 05-08-2025
- BIOA 05-15-2025
- Dividend Yield
- RAPT N/A
- BIOA N/A
- EPS Growth
- RAPT N/A
- BIOA N/A
- EPS
- RAPT N/A
- BIOA N/A
- Revenue
- RAPT N/A
- BIOA N/A
- Revenue This Year
- RAPT N/A
- BIOA N/A
- Revenue Next Year
- RAPT N/A
- BIOA N/A
- P/E Ratio
- RAPT N/A
- BIOA N/A
- Revenue Growth
- RAPT N/A
- BIOA N/A
- 52 Week Low
- RAPT $0.79
- BIOA $2.88
- 52 Week High
- RAPT $8.58
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- RAPT 31.31
- BIOA N/A
- Support Level
- RAPT $0.81
- BIOA N/A
- Resistance Level
- RAPT $0.98
- BIOA N/A
- Average True Range (ATR)
- RAPT 0.10
- BIOA 0.00
- MACD
- RAPT -0.03
- BIOA 0.00
- Stochastic Oscillator
- RAPT 7.72
- BIOA 0.00
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.